Adding trastuzumab to carboplatin and paclitaxel is safe and effective among patients with advanced or recurrent uterine serous carcinoma with overexpressed HER2/neu, according to a presentation at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans.1

Carboplatin/paclitaxel is an established treatment for uterine serous carcinoma, a rare and aggressive subtype of endometrial cancer. For this phase 2 study (ClinicalTrials.gov Identifier: NCT01367002), researchers evaluated whether adding trastuzumab, which inhibits HER2/neu, to this combination would improve outcomes among patients with advanced/recurrent disease with overexpressed HER2/neu. The primary endpoint was progression-free survival (PFS).

Sixty-one patients were randomly assigned to receive carboplatin/paclitaxel or carboplatin/paclitaxel with trastuzumab. All patients had stage III to IV primary or recurrent disease. Fifty-eight patients were evaluable for PFS.

Related Articles

The overall median PFS was 12.6 in the trastuzumab arm vs 8 months in the control arm (hazard ratio [HR], 0.44; P = .005). Patients treated for primary disease (41 patients) had a median PFS of 17.9 months in the trastuzumab arm vs 9.3 in the control arm (HR, 0.40; P = .013); patients with recurrent disease (17 patients) had a median PFS of 9.2 vs 6 months in the experimental vs control arm, respectively (HR, 0.14; P = .003).

Toxicity was similar in both arms.

The authors concluded that adding “trastuzumab to carboplatin-paclitaxel was well-tolerated and increased PFS. This regimen may come to represent the new standard of care for women with advanced or recurrent uterine serous carcinoma who overexpress Her2/neu.”

Reference

Santin AD, Fader AN. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002). Oral presentation at: 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 24-27, 2018; New Orleans, LA.

This article originally appeared on Cancer Therapy Advisor